SAKAR Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹70 Cr
verified against source
Revenue YoY
62%
reported change
EBITDA
₹18.59 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Sakar Healthcare delivered a standout Q3 FY26 with revenue from operations at Rs 70.34 crore, up 62% YoY driven by 31 crore oncology revenue (19 crore exports, 12 crore domestic). EBITDA grew 58% to Rs 18.59 crore with 26% margin. PAT surged 126% to Rs 10.25 crore. The EU GMP-approved Baddi oncology facility is the key differentiator, with 11 marketing authorizations received and 102 dossiers submitted globally. Tech transfer partnerships with Accord, Torrent, Glenmark, and Zydus provide long-term revenue visibility. Management targets 30% EBITDA margins as oncology scales, with 60-70% oncology growth projected for FY27. First EU commercial supplies to Bulgaria/Bosnia expected from Q1 FY27. Key risks include regulatory approval timelines, competitive intensity in TKI space, and partner-dependent commercialization. Tax rate normalizing to ~25% post-FY27 after MAT credit utilization.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects oncology segment to grow 60-70% year-on-year in FY27, building on Q3 FY26's 31 crore quarterly revenue base. 9-month oncology revenue stands at 69.45 crore.
- As oncology scales up further, management targets EBITDA margins around 30%, up from current 26%, with improved operating leverage and product mix benefits.
- 10 tech transfer molecules from Accord and other partners represent Rs 50-100 crore revenue potential. Second imatinib product already approved; 2 more molecules expected within next 2 months, 3 in following quarter, completing tech transfers by Q1 FY27.
- 9-month capex of Rs 39 crore completes planned capacity expansion. Maintenance capex at ~Rs 65 lakh per quarter. No major capex planned for FY27.
Risks flagged
- EU marketing authorizations follow 210 working day standard timeline, with query-driven stop clocks adding uncertainty. Obtaining approval slots in Europe is described as the primary challenge.
- Another Indian pharma player with TKI focus has achieved meaningful EU revenue traction. Sakar's competitiveness depends on partner selection and market penetration in respective European territories.
- Sakar relies on partners (Accord, Torrent UK, Glenmark, Zydus, Hyman Germany) for EU market access. First commercial supply to Bulgaria/Bosnia faces 90-150 day lead times; margins on Accord business at 24-26% EBITDA.
- Lower tax provision (18-19%) due to MAT credit utilization will normalize to ~25% post-FY27, creating a potential headwind to net income growth.
Key quotes
- We have already received five marketing authorizations from the EU region and one from entire Europe extra that is total six. Now considering that we are currently having submitted another 18-19 dossiers in across Europe. So these are about to come up and these will add up to the overall list of marketing authorizations within the next financial year.
- We have developed full basket of 10-12 products which we have developed. So this is a unique feature which we presently hold and which our competitors are not having.
- This is the only first of a series of oncology products expected to be commercialized through similar regulatory pathways. Our dossier progress has remained strong of 211 oncology dossiers submitted globally.
Research modules